Quantcast

The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism

Research paper by S. A. R. Webb, S. Stott, P. V. van Heerden

Indexed on: 01 Apr '96Published on: 01 Apr '96Published in: Intensive Care Medicine



Abstract

To describe the use of inhaled aerosolized prostacyclin (IAP) in a patient with life-threatening pulmonary hypertension secondary to pulmonary embolism and to discuss the possible use of inhaled prostacyclin in the management of pulmonary embolism.Case report.Intensive care unit of a university teaching hospital.One patient with severe pulmonary hypertension secondary to acute-on-chronic pulmonary embolism.Conventional medical management of massive pulmonary embolism and inhaled aerosolized prostacyclin (IAP).Description of clinical course, haemodynamic data and gas exchange data.We describe a patient with massive pulmonary embolism for whom the addition of IAP to his therapy appeared to result in a transient improvement in pulmonary haemodynamics and gas exchange.